Leading Chinese Biotech Firm 3SBio Lays Groundwork For Foray Into Biosimilars In U.S., EU Markets
This article was originally published in The Pink Sheet Daily
New biologics plant will quadruple the firm's capacity by the end of the year, enabling commercialization of biosimilars in more developed countries and markets, COO says.
You may also be interested in...
SHANGHAI - 3SBio filed an application for the approval of NuLeusin with China's State FDA Nov. 10, hoping to make it the first product of its kind on the Chinese market, the Shenyang-based company announced
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.